Children - Articles - Page 2 | CARLAT PUBLISHING

Expert Q&A

Tolerability of Vortioxetine for Pediatric Anxiety and Depressive Disorders

January 1, 2024

Kathryn Martin, MD, MPH. Dr. Martin discloses that she owns shares in a variety of pharmaceutical companies. Relevant financial relationships listed for the author have been mitigated.

Vortioxetine has to be reasonably tolerated in children and teens, with manageable side effects, to have any chance of inclusion into treatment for anxiety or depression. This research update gives you the latest on whether vortioxetine might be a viable approach even before we have good efficacy studies.

Research Update

Does Adding Topiramate to Aripiprazole for Mania Improve Metabolic Outcomes?

January 1, 2024

Dorothy Chyung, MD

Dorothy Chyung, MD. Dr. Chyung has no financial relationships related to this material.

We struggle to manage the metabolic impact of antipsychotic medications on the children and teens we treat. Could topiramate be a viable option for our armamentarium of strategies? Read our research update to find out.

Clinical Update

Lithium for Children and Adolescents

November 2, 2023

Max S. Rosen, MD

Max S. Rosen, MD. Assistant Professor of Psychiatry (Child); Director, Child & Adolescent Psychiatry Outpatient Services; Washington University School of Medicine, St. Louis, MO.

Dr. Rosen has no financial relationships with companies related to this material.

Lithium is FDA-approved for bipolar disorder in children and adolescents 12 years and up; however, its potential off-label utility is broad, from affective aggression to anorexia nervosa. This clinical update covers how to prescribe lithium for children and adolescents and how to talk with patients and parents about lithium.

Research Update

Efficacy of Deep Brain Stimulation for OCD

November 1, 2023

John Raiss, MD

John Raiss, MD. Dr. Raiss has no financial relationships with companies related to this material.

Deep Brain Stimulation is a surgically invasive procedure that is used in an attempt to treat several conditions including obsessive compulsive disorder in some youths. But does it work? Read our research update so you can better guide families on this high-risk decision.

Research Update

Antipsychotics in Pregnancy and Risk of Neurodevelopmental Disorders

October 3, 2023

Sébastien Hardy, PharmD, BCPS.

Sébastien Hardy, PharmD, BCPS. Dr. Hardy has no financial relationships with companies related to this material.

This large study gives us reassuring data about neurodevelopmental outcomes in children exposed to several second-generation antipsychotic medications during pregnancy.

The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths

May 20, 2021

John Raiss, MD.

John Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When is the best time to begin gender affirming medical care (GAMC) with respect to addressing the mental health status of children and adolescents with Gender Dysphoric Disorder? Should we begin Hormone Replacement Therapy early or wait until the adolescent is older? This research update will help you grapple with this very public debate.

EXPERT Q&A

Duty to Warn? Debating Antidepressant Suicidality

October 30, 2020

Martha J. Ignaszewski, MD and Glen Spielmans, PhD

Martha J. Ignaszewski, MD
Fellow, University of California, San Francisco

Glen Spielmans, PhD
Professor of Psychology, Metropolitan State University, St. Paul, MN

Dr. Ignaszewski and Dr. Spielmans have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For 16 years, since the FDA black box warning about suicidality with antidepressants, our community has been quoting data that downplays this concern. We were wrong. We were deceived. Antidepressants can be lifesaving, but there really is a duty to warn. Drs. Martha Ignazewski and Glen Speilmans talk with us about what went on and how to talk about it with our families.

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

June 11, 2019

With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.

Medications for Depression

June 11, 2019

Martha J. Ignaszewski, MD

Martha J. Ignaszewski, MD

Chief Fellow, Clinical Fellow in Psychiatry at Boston Children’s Hospital

Dr. Ignaszewski has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we review the findings of placebo- controlled trials done over the past 10 years on depression in kids and the discuss the current recommendations for medication treatment of depression in children and adolescents.

Practical Approaches to Vetting Clinical Research

June 11, 2019

Darren B. Courtney, MD, FRCPC

Darren B. Courtney, MD, FRCPC

Staff Psychiatrist for the Youth Addictions and Concurrent Disorders Service at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada

Dr. Courtney has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we discuss how to use the PICOT method to efficiently frame the clinical questions that arise in everyday practice. We also examine the hierarchy in terms of the types of studies that are most useful for the busy clinician to look at and provide a corresponding table covering the categories of evidence for clinical practice.